Apimeds Pharmaceuticals US, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-09-25. It has amended it 7 times. It filed its final prospectus on 2025-05-09. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on the NYSE American (the “NYSE American”) under the symbol “APUS.”From the 424B4 filed 2025-05-09
Use of proceeds
We intend to use the net proceeds we receive from this offering to fund our Phase III clinical trial in knee OA, to initiate at least one non -registered company sponsored trials in MS, manufacturing costs, to repay current debt liabilities, and any remaining amounts to fund working capital and general corporate purposes.From the 424B4 filed 2025-05-09
Revenue
Our company will remain an SRC until the last day of the fiscal year in which it had (i) a public float that exceeded $250 million or (ii) annual revenues of more than $100 million and a public float that exceeded $700 million.From the S-1/A filed 2025-02-10
Net loss or income
Our net losses were $1,078,357 and $210,728 for the nine months ended September 30, 2024 and 2023, respectively.From the S-1/A filed 2025-02-10
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-09-25 | Registration statement filed | S-1 |
| 2024-11-08 | Registration statement amended | S-1/A |
| 2024-12-09 | Registration statement amended | S-1/A |
| 2024-12-20 | Registration statement amended | S-1/A |
| 2025-01-10 | Registration statement amended | S-1/A |
| 2025-01-29 | Registration statement amended | S-1/A |
| 2025-02-06 | Registration statement amended | S-1/A |
| 2025-02-10 | Registration statement amended | S-1/A |
| 2025-05-09 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Apimeds Pharmaceuticals US, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.